ICER Draft Report: High-Cost GLP-1 Obesity Drugs Deemed Cost-Effective—Affordability Still a Concern

The Institute for Clinical and Economic Review (ICER) released a draft report in September 2025 finding that GLP-1 weight-loss drugs, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), are now considered cost-effective due to reduced prices and demonstrated heart-health benefits24.

ICER’s analysis indicates these medications now provide greater economic value than lifestyle interventions alone, supporting their use from a value-based pricing perspective24.

Prices for major GLP-1 drugs have dropped in recent years, with semaglutide’s net price at $6,830 and tirzepatide’s at $7,973 per year, contributing to improved cost-effectiveness ratings4.

Despite their value, ICER highlights that growing demand for GLP-1 obesity medicines in a large population is causing significant affordability concerns for insurers and employers, threatening the sustainability of widespread access23.

The report emphasizes the need for coordinated national strategies and policy reforms to balance broad patient access with overall healthcare affordability35.

Sources:

2. https://www.ainvest.com/news/glp-1-weight-loss-drugs-cost-effective-icer-report-2509/

3. https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-releases-obesity-medications-white-paper-examining-strategies-to-ensure-affordable-access/

4. https://www.ainvest.com/news/glp-1-drugs-deemed-cost-effective-icer-report-suggests-2509/

5. https://icer.org/assessment/strategies-affordable-access-for-obesity-medications-2025/